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Pancreatic cancers driven by KRAS mutations require additional mutations for tumor progression. The tumor
suppressor FBXW7 is altered in pancreatic cancers, but its contribution to pancreatic tumorigenesis is unknown.
To determine potential cooperation between Kras mutation and Fbxw7 inactivation in pancreatic tumorigenesis,
we generated P48-Cre;LSL-KrasG12D;Fbxw7 fl/fl (KFCfl/fl) compound mice. We found that KFCfl/fl mice displayed
accelerated tumorigenesis: all mice succumbed to pancreatic ductal adenocarcinoma (PDA) by 40 days of age,
with PDA onset occurring by 2 weeks of age. PDA in KFCfl/fl mice was preceded by earlier onset of acinar-to-ductal
metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) lesions, and associated with chromosomal
instability and the accumulation of Fbxw7 substrates Yes-associated protein (Yap), c-Myc, and Notch. Using KFCfl/
fl and FBXW7-deficient human pancreatic cancer cells, we found that Yap silencing attenuated growth promotion
by Fbxw7 deletion. Our data demonstrate that Fbxw7 is a potent suppressor of KrasG12D-induced pancreatic
tumorigenesis due, at least in part, to negative regulation of Yap.
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Pancreatic cancer has an overall 5-year survival rate of 8% and is
currently the fourth leading cause of cancer-related death in the
United States. Nearly all human pancreatic cancers are characterized
by mutations in KRAS followed in order of mutational frequency by
P16, P53, and DPC4 [1]. Genetically engineered Kras mutant mouse
models of pancreatic cancer recapitulate the human disease process
beginning with acinar-to-ductal metaplasia (ADM), followed by
pancreatic intraepithelial neoplasia (PanIN) formation, and ultimate-
ly pancreatic ductal adenocarcinoma (PDA) [2]. The introduction of
other mutations such as p53, p16, or Dpc4 further accelerates the
development of PDA. Using an inducible Kras mutant (G12D)
mouse model, it was shown that Krasmutation is involved not only in
initiation but also in the maintenance of PDA, as inactivation of
mutant Kras in established tumors leads to tumor regression [3].
Furthermore, tumor regrowth following inactivation of mutant Kras
involves expression of Yap which is also required for initiation of PDA
in Kras mutant mice [4,5].FBXW7, a component of the Skp1-Cullin1-Fbox E3 ubiquitin
ligase complex, is a characterized tumor suppressor. For instance,
conditional Fbxw7 deletion cooperates with APC mutation or P53
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manner [6,7]. Although FBXW7 is most frequently mutated in
colorectal, uterine, and bladder cancers, it is also a significantly
mutated gene in pancreatic cancers [8,9]. Furthermore, in a Sleeping
Beauty transposon insertional mutagenesis model of KrasG12D-induced
pancreatic tumorigenesis, Fbxw7 mutation cooperated with KrasG12D
to accelerate PDA formation with a high frequency (24%), suggesting
that Fbxw7 may be an important tumor suppressor in Kras-driven
pancreatic cancers [10]. In addition to mutation, there is also emerging
evidence to suggest that FBXW7 is altered by other mechanisms in
pancreatic cancers including by reduced gene expression and heightened
protein degradation which correlate with reduced survival [11].
Although the tumor suppressor functions of FBXW7 have largely
been attributed to its proteolytic regulation of oncogenic substrates
such as Cyclin E, c-MYC, Notch, and c-JUN, FBXW7 regulates over
30 substrates and likely unknown substrates as well [12,13]. Loss of
FBXW7 promotes genomic instability in part by increased Cyclin E
expression [14] which may contribute to tumorigenesis. We have
recently reported that FBXW7 regulates nonhomologous end-joining
(NHEJ) via K63-linked polyubiquitination of XRCC4, promoting
the interaction of XRCC4 with DNA double-strand breaks and other
core NHEJ proteins [15]. This direct involvement of FBXW7 in
NHEJ may also contribute to the genomic instability and
tumorigenesis in FBXW7-deficient models.
Because pancreatic cancer is characterized most frequently by
KRAS mutation (~100%) [1] as well as mutations or reduced
expression of FBXW7 in a subset of human pancreatic cancers
[8,9,11], in this study, we investigated whether FBXW7 acts as a
tumor suppressor in KrasG12D-driven pancreatic tumorigenesis.
Using a pancreas conditional P48-Cre;LSL-KrasG12D;Fbxw7fl/fl
mouse model, we found that homozygous deletion of Fbxw7 causes
a dramatic acceleration of KrasG12D-driven pancreatic tumorigenesis.
Based on this finding, we went on to investigate the contribution of
Fbxw7 substrates, such as Yap, to the mechanisms of tumorigenesis in
both mouse and human pancreatic cancer cells.Materials and Methods
Mouse Strains
The conditional LSL-Fbxw7 flox/flox mouse was a gift fromDr. Iannis
Aifantis (New York University) [16]. Conditional LSL-Fbxw7 flox/flox;
LSL-KrasG12D/+; and P48-Cre strains were interbred to obtain
LSL-KrasG12D/+; LSL-Fbxw7 flox/flox; P48-Cre triple mutant animals
(KFC). Themice were housed in specific pathogen-free facilities, and all
the studies were conducted in compliance with the Institutional
Committee on Use and Care of Animals guidelines. Genotyping was
carried out by tail clipping frommice 2weeks after birth. Tail specimens
were incubated for 24 hours at 55°C in tail-lysis buffer containing
proteinase K. NaCl was added, and cellular debris were pelleted by
centrifugation. DNA was precipitated by the addition of isopropanol
and washed with 70% ethanol. DNA pellets dissolved in water were
used for polymerase chain reaction (PCR) analysis.
Cell Lines
Panc-1 cells were obtained from the American Type Culture
Collection. Cells were cultured in Dulbecco's modified Eagle
medium supplemented with 10% FBS, 2 mM glutamine, and
antibiotics. The KFC cell line was derived from the tumor of a
3-week-old KFC mouse. Briefly, mouse pancreas was harvested andfinely minced and incubated with a Collagenase V/HBSS (with Ca
and Mg) solution at 37°C under constant shaking for 1.5 hours.
Collagenase digestion of pancreas tissue was neutralized by
RPMI-1640 medium containing 10% FBS. Digested tumor cells
were filtered through a 40-μm filter and then cultured in RPMI-1640
medium containing 10% FBS, 2 mM glutamine, and antibiotics.
Acinar Cell Culture
The 3D culture of pancreatic acinar cells was prepared by digesting
pancreata from 1-week-old mice with Collagenase P followed by
culture in Matrigel as previously described [17]. Briefly, pancreata
from KFC, KC, and control mice were cut into small pieces and
digested with 2 mg/ml of Collagenase P (Roche Diagnostics) in HBSS
for 15 minutes at 37°C. Cells were then washed three times with
HBSS with 5% FBS and filtered through 100-μm nylon meshes.
After centrifugation, the cell suspension was mixed 1:1 with Matrigel
and plated onto the collagen layer. The acinar cell/Matrigel mix was
allowed to solidify for 1 hour at 37°C before adding medium. The
formation of ductlike structures was observed at days 1, 2, and 3.
Histopathologic Analysis
Histopathologic analysis was conducted by a pathologist (Y.Z.) on
all deidentified hematoxylin and eosin (H&E)–stained slides.
Pancreata sections were evaluated for ADM, PanIN1, PanIN2,
PanIN3, and PDA lesions based on a previously reported
classification system [2]. Pancreata were diagnosed according to the
most severe phenotype observed, and data were expressed as the
percentage of animals with each phenotype.
Immunohistochemistry and Immunoblotting
Immunohistochemistry was conducted as previously described [3].
Images were acquired with an Olympus BX-51 microscope, Olympus
DP71 digital camera, and DP Controller software. Antibodies used for
immunohistochemistry include those recognizing YAP (Cell Signaling,
#4912, 1:500), c-MYC (Abcam, ab32072, 1:200), Notch (Cell Signaling,
#3608, 1:250), Ki67 (BD Bioscience, Cat. 550609, 1:500), CK19
(Abcam, ab87000, 1:500), and Amylase (Sigma-Aldrich, A8273, 1:500).
Immunoblotting was conducted as previously described [15].
FBXW7 was detected by FBXW7 immunoprecipitation followed by
immunoblotting. Antibodies used for immunoblotting in this study
include those recognizing FBXW7 (Bethyl, A301-720A, 1:1000,
overnight, 4°C), YAP (Cell Signaling, #4912, 1:3000, overnight, 4°C),
c-MYC (Abcam, ab32072, 1:2000, overnight, 4°C), Notch (Cell
Signaling, #3608, 1:2000, overnight, 4°C), c-JUN (Cell Signaling,
#9165, 1:1000, overnight, 4°C), MCL-1 (Santa Cruz, sc-819, 1:1000,
overnight, 4°C), Cyclin E (Santa Cruz, sc-198, 1:1000, overnight, 4°C),
mTOR (Cell Signaling, #2972, 1:1000, overnight, 4°C), and actin
(Sigma Aldrich, Clone AC-40, 1:5000, overnight, 4°C).
Lentivirus-Based shRNA Infection and siRNA Transfection
Cells were infected with lentivirus (control 5′-GCAAGCT
GACCCTGAAGTTCAT-3′; FBXW7: 5′-ACAGGACAGTGTTTA
CAAA-3′) in the presence of 8 μg/ml of polybrene. Silencing efficiency
was detected 72 hours after infection by immunoblot. For Yap RNAi
experiments, cells were transfected with Oligofectamine (Invitrogen)
transfection reagent. The two independent siYap oligonucleotide
sequences used were 5′-CCACCAAGCUAGAUAAAGA-3′ (siYap-2)
and 5′-GCACCUAUCACUCUCGAGA-3′ (siYap-4). Nonspecific
siRNA was used as a control.
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Cells were infected with shRNA (FBXW7 or control) and then
transfected with Yap siRNA. After 3 days, cells were seeded in
triplicate in 60-mm dishes and allowed to form colonies for 9 to 14
days. KFC pancreatic tumor cells were transfected with two
independent siYap oligonucleotides. Two days posttransfection,
KFC cells were seeded to form colonies for 14 days. Colonies were
fixed with 100%methanol, stained with methylene blue in methanol,
and then scored.
Statistical Analysis
Survival curves were calculated according to the Kaplan-Meier
method, and statistical differences were analyzed by the log-rank and
Gehan-Breslow-Wilcoxon tests using GraphPad Prism. A two-sided,
unpaired Student's t test was used for other statistical analyses.
P values of b .05 were considered statistically significant.
Results
Acceleration of KrasG12D-Pancreatic Tumorigenesis by Fbxw7
Deletion
To investigate the involvement of FBXW7 in mutant KRAS-driven
pancreatic tumorigenesis, we crossed P48-Cre;LSL-KrasG12D mice [2]
with Fbxw7 fl/fl mice [16] to generate mice with pancreas specific
activation of KrasG12D and heterozygous or homozygous deletion of
Fbxw7 (designated KFCfl/+ or KFCfl/fl, respectively; Figure 1A). We
first confirmed deletion of Fbxw7 by examining Fbxw7 protein levels in
pancreata from 1-week-old mice and found Fbxw7 protein to be
substantially reduced in pancreata from KFCfl/fl mice compared with
those from KC control mice or KFCfl/+ mice (Figure 1B). To begin to
establish a phenotype for these mice, survival was monitored in KC,
KFCfl/+, KFCfl/fl as well as in FCfl/fl mice. We observed a profound
effect of homozygous Fbxw7 deletion on survival of KFCfl/fl mice
(Figure 1C) with a median survival time of 28.5 days. Most KFCfl/fl
displayed early symptoms of morbidity and were euthanized; 100% of
KFCfl/fl mice succumbed to PDAby 40 days comparedwith only 7%of
KFCfl/+ and none of the KC or FCmice during the observation period.
Gross examination of KFCfl/fl mice revealed smaller body size, enlarged
pancreata, ascites, and duodenum adhesions inmostmice with pancreas
main duct obstruction and liver metastases occurring in a subset of mice
(Supplementary Figure 1, A–E). Histological examination of pancreas
sections from 1-month-old KFCfl/fl mice revealed moderately to poorly
differentiated PDA accompanied by PanIN3 lesions (Figure 1D).
In contrast, pancreata from KC or FCfl/fl mice appeared largely
normal, although early-stage PanIN lesions were occasionally observed
inKFCfl/+ pancreata (Supplementary Figure 1F). To further explore the
effects of heterozygous Fbxw7 deletion, we also examined pancreata
from 6-month-old mice. Whereas KC mice showed some PanIN
lesions, KFCfl/+ contained more PanIN lesions, ranging from PanIN1A
through PanIN3 in both genotypes, but no PDA (Figure 1D).
Pancreata from FCfl/fl mice were overall normal with the exception of
occasional enlarged ductal cells, consistent with a prior study [18]
(Supplementary Figure 1G).
Tumorigenesis in KrasG12D;Fbxw7-Deleted Pancreata Is
Preceded by ADM and PanIN and Associated with
Chromosomal Instability
We then sought to characterize the progression of precursor lesions
leading to PDA in KFCfl/fl mice. To this end, pancreata from 1-, 2-,
and 3-week-old KC, KFCfl/+, and KFCfl/fl mice were examinedhistologically and scored for the presence of ADM, PanINs, and
PDA. In KC and KFCfl/+ mice at 1 to 2 weeks of age, pancreata were
composed mainly of acinar cells with no observable ADM or PanIN
lesions (Figure 2, A and B). By 3 weeks of age, pancreata from KC
and KFCfl/+ mice began to develop ADM with progression toward
PanIN2 in the KFCfl/+ mice. In striking contrast, KFCfl/fl pancreata
contained PanIN1 and PanIN2 lesions as well as stroma accumula-
tion at 1 week, which advanced to a combination of PanIN3 and
PDA at 2 weeks. By 3 weeks of age, 100% of KFCfl/fl pancreata
contained PDA. To confirm the acceleration of ADM in KFCfl/fl
pancreata, we used 3D cultures of acinar clusters and observed the
formation of ductlike structures by as early as 1 day in KFCfl/fl acini
(Figure 2, C and D). Further characterization of KFCfl/fl pancreata
showed increased CK19, decreased amylase, and increased Alcian
Blue staining, confirming ADM and progression toward PanIN
lesions, respectively (Supplementary Figure 2).
Genomic deletion or mutation of FBXW7 has been associated with
genomic instability in various cancers [6,14,19,20]. Given the high
degree of chromosomal instability (CIN) in human PDA, we
examined KFCfl/fl pancreatic tumors for signs of CIN and
found abnormal mitotic figures (Supplementary Figure 3A).
Furthermore, using a cell line derived from KFCfl/fl pancreatic
tumors (Supplementary Figure 3B), we found increased numbers of
micronuclei, which are commonly observed in cells with CIN
(Supplementary Figure 3C). Consistent with this finding, flow
cytometry also revealed that theKFC tumor cell line, aswell as the established
KPC cell line (with p53 deletion), is aneuploid (Supplementary Figure 3D).
These data suggest that CIN is associated with the accelerated pancreatic
tumorigenesis observed in KFCfl/fl mice.
Accumulation of Fbxw7 Substrates in Fbxw7-Deleted Pancreata
To begin to determine the mechanisms leading to accelerated
pancreatic tumorigenesis in the KFCfl/fl mice, pancreata from
1-week-old mice were analyzed for expression of oncogenic substrates
of Fbxw7 [12,13]. We hypothesized that Fbxw7 substrates involved
in KrasG12D-driven tumorigenesis would be accumulated in response
to homozygous Fbxw7 deletion. Of the substrates investigated, we
found that the levels of c-Myc, Yap, and Notch, but not c-Jun, Cyclin
E, and Mcl-1, were elevated in KFCfl/fl pancreata as well as in the
KFCfl/+ pancreata, although to a lesser extent (Figure 3A). Evaluation
of these proteins immunohistochemically confirmed their increased
expression within aberrant ductal structures in KFCfl/fl pancreata
(Figure 3B). In addition, we also assessed the proliferative marker
Ki67 and found significantly higher levels of Ki67 in KFCfl/fl
pancreata (Figure 3B, Supplementary Figure 4A). These changes in
KFCfl/fl pancreata appeared to be independent of Kras activity, as
downstream effectors of Kras (pErk1/2 and pAkt) were not elevated
in KFCfl/fl pancreata (Supplementary Figure 4B). Taken together,
these data demonstrate an association between increased c-Myc, Yap,
and Notch expression and KrasG12D-induced tumorigenesis in
Fbxw7 homozygous deleted mice.
Rescue of Growth Promotion Caused by Fbxw7 Deletion by
Depletion of Yap
Based on recent studies implicating Yap in KrasG12D-induced
pancreatic tumorigenesis [4,5], we hypothesized that Fbxw7 may
promote tumorigenesis through a Yap-dependent mechanism. To test
this hypothesis, we first evaluated the ability of Fbxw7 to regulate Yap
protein levels in a cell line established from KFCfl/fl pancreatic
Figure 1. Deletion of mouse Fbxw7 accelerates KrasG12D-driven pancreatic tumorigenesis. (A) Genetic makeup of the KFC model. (B) Western
blot analysis of Fbxw7protein levels inKC,KFCfl/+, andKFCfl/fl pancreata specimens from1-week-oldmice. (C) The survival of KC, FC, KFCfl/+, and
KFCfl/fl mice is expressed using the Kaplan-Meier method, and statistically significant differences from KCmice are shown (P b .0001****). (D)
H&E staining of pancreata at 1 and 6 months. Scale bar, 100 μm. Each image is representative of at least three independent animals.
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from KC mice (relative to KFC), exogenously expressed FBXW7
reduced Yap, c-Myc, and Notch protein levels in primary KFC-derived
cells (Figure 4A) without substantial changes in other Fbxw7 substrates
(Cyclin E, Mcl-1, mTOR; Supplementary Figure 5A). We then
depleted Yap from KFC cells to determine its contribution to the
increased growth of KFC cells and found that Yap depletion caused a
significant decrease in the growth of KFC cells which was similar to
the effect observed by exogenous FBXW7 expression (Figure 4B).
Interestingly, Yap depletion was also associated with reduced c-Myc
protein levels (Figure 4A). To further define the role of YAP in
KFCfl/fl tumorigenesis, we utilized human pancreatic cancer cellsthat were deleted of FBXW7 by shRNA and then further silenced for
YAP by siRNA. FBXW7 shRNA-treated Panc-1 and MiaPaCa-2 cells
demonstrated increased levels of YAP and c-MYC levels without change in
other FBXW7 substrates (Figure 4C; Supplementary Figure 5, B and C).
Silencing of YAP by either of two independent siRNAs caused a reduction
in c-MYC protein levels and, more importantly, significantly inhibited
the growth of FBXW7-deficient human pancreatic cancer cells (Figure 4D,
Supplementary Figure 5D). These results are consistent with the
accelerated tumorigenesis and increased Yap levels observed in KFCfl/fl
pancreata. Taken together, these data demonstrate that Yap accumu-
lation is causally related, at least in part, to the accelerated growth
observed in Fbxw7-deficient, Kras mutant pancreatic cancer cells.
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In this study, we show for the first time that Fbxw7 is a suppressor of
Kras mutation-driven pancreatic tumorigenesis. The dramatically
accelerated tumorigenesis observed in the KFCfl/fl mice was associated
with accumulation of oncogenic Fbxw7 substrates such as c-Myc,
Notch, and Yap. Importantly, we found that Yap expression was a
driving mechanism of the accelerated tumorigenesis in response toFbxw7 deletion given that Yap depletion attenuated growth in both
KFC primary cells as well as FBXW7-deficient human pancreatic
cancer cells. These findings suggest that alterations in FBXW7may be
an important contributor to human pancreatic tumorigenesis.
Furthermore, our data suggest that Fbxw7 is a relatively potent
suppressor of pancreatic tumorigenesis given the development of
tumors by less than 1 month in response to Fbxw7 deletion relative to
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Figure 3. Analysis of Fbxw7 substrates in pancreata. (A) Western blot analysis of the indicated proteins in lysates obtained from pancreata
of 1-week-old mice for each of the indicated genotypes. (B) Immunohistochemical assessment of Yap, c-Myc, Notch, and Ki67 in KC,
KFCfl/+, and KFCfl/fl pancreata at 1 week. Scale bar, 100 μm.
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p16Ink4a, P53, and Dpc4) [21–23].
Although FBXW7 is most frequently mutated in colorectal,
uterine, and bladder cancers, it is also a significantly mutated gene
in pancreatic cancers [8,9]. FBXW7 mutations are generally
heterozygous, missense, loss-of-function mutations occurring in theWD domain that function in a dominant negative manner [13,24].
There are however emerging evidence also to suggest that FBXW7 is
altered by other mechanisms in pancreatic cancers including by
reduced gene expression and heightened protein degradation [11]. It
is important for future studies to define the spectrum of genetic and
posttranslational alterations of FBXW7 in both primary and
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c-Myc, Yap, and Notch proteins in KFC primary tumor cells with depletion of Yap. FLAG-FBXW7 overexpression in KFC tumor cells was
used as a control. (B) The growth of KFC primary cells wasmeasured with or without Yap depletion by colony forming assays. (C) Western
blot detection of YAP, c-MYC, Notch, and FBXW7 levels in Panc-1 cells with or without FBXW7 and/or YAP depletion. (D) The growth of
Panc-1 cells with or without FBXW7 and/or YAP depletion was assessed by colony formation assays. Images are representative of at least
two independent experiments (A, C). Data are expressed as themean ± SE of three independent experiments, and statistical significance
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of KRAS and FBXW7 mutations in colorectal cancers, studies to
investigate their effects on intestinal tumorigenesis are warranted.
Prior studies have shown that Fbxw7 is a haploinsufficient tumor
suppressor [7,25]. In mice with P53 deletion, heterozygous Fbxw7
deletion resulted in the development of multiple tumor types [25].
Similarly, intestinal tumorigenesis in APC mice was accelerated by
heterozygous deletion of Fbxw7 [7]. In the current study, we found
that homozygous deletion of Fbxw7 produced a dramatic acceleration
of pancreatic tumorigenesis that was not observed under heterozygous
conditions. However, consistent with a haploinsufficient function of
Fbxw7, KFCfl/+ mice did have an increased frequency of PanIN lesions
relative to KCmice (Figure 2B), leading to the development of PDA in a
subset of these mice (7%). Taken together, these results are consistent
with a haploinsufficient effect of Fbxw7 on PanIN development
but clearly demonstrate that the most profound effects of Fbxw7 on
KrasG12D-induced tumorigenesis require homozygous deletion.
Our findings implicate Yap accumulation as being causally related,
at least in part, to the accelerated growth observed in Fbxw7-deficient,Kras mutant pancreatic cancer cells. Furthermore, it is also possible
that YAP accumulation is associated with the observed genomic
instability, as other studies have shown that YAP can promote
genomic instability [26]. Interestingly, we also found c-Myc, another
established Fbxw7 substrate, consistently elevated in KFCfl/fl
pancreata and FBXW7-deficient human pancreatic cancer cells.
Although it is conceivable that direct regulation of c-Myc by Fbxw7
could be a mechanism of tumorigenesis, Yap depletion led to reduced
expression of c-Myc (Figure 4, A andC, and Supplementary Figure 5C).
This finding, together with a recent report demonstrating
YAP-dependent c-MYC expression [27], suggests that c-Myc
may function downstream of Yap in KrasG12D-induced pancreatic
tumorigenesis. Future studies are required to fully define the
mechanisms of Fbxw7-mediated regulation of Yap and c-Myc in
pancreatic tumorigenesis.
In conclusion, this study demonstrates that Fbxw7 suppresses
KrasG12D-induced pancreatic tumorigenesis via a Yap-dependent
mechanism. These findings suggest that YAP and the Hippo pathway
should be explored as a therapeutic strategy in pancreatic cancers with
Neoplasia Vol. 18, No. 11, 2016 Pancreatic Tumorigenesis by Fbxw7 Deletion Zhang et al. 673FBXW7 alterations. Furthermore, based on the genomic instability
associated with FBXW7 deletion [14,15], investigation of therapeutic
strategies exploiting DNA damage repair pathways is warranted for
cancers with FBXW7 alterations.
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